DSM Signs Supply Pacts with Opthea and Sanquin - - BioPharm International

ADVERTISEMENT

DSM Signs Supply Pacts with Opthea and Sanquin



Untitled Document

DSM Pharmaceutical has developed supply pacts with Opthea and Sanquin. The agreement with Opthea of Melbourne, Australia covers process development and cGMP manufacture by DSM for Opthea's lead molecule, a soluble form of human VEGFR-3 that blocks the activity of both VEGF-C and VEGF-D, which promote blood and lymphatic vessel formation and are involved in the progression of eye diseases.

This project represents an agreement for process development at DSM Biologics' Groningen, the Netherlands, facility and manufacture at the company’s newly established cGMP facility in Brisbane, Australia. Opthea, a private 100% owned subsidiary of Circadian Technologies is developing its lead molecule OPT-302, previously known as VGX-300, initially for the treatment of "wet" (neovascular) age-related macular degeneration.

In other news, DSM has signed an agreement with the Sanquin Blood Supply Foundation for the commercial manufacture of a monoclonal antibody (mAb) used for the recovery and purification of coagulation factor IX from human blood. Collaboration between DSM Biologics, a business unit of DSM Pharmaceutical Products, and Sanquin will entail subsequent GMP manufacture of the antifactor IX mAb at DSM Biologics’ facilities in Groningen, the Netherlands.

DSM becomes a second supplier to Sanquin for a process intermediate that is used for the capture of human factor IX from blood plasma.

Source: DSM Pharmaceutical

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines

Click here